// App-Quantinova.ai

3678 : Phase 1b Study of TRU-016, an Anti-CD37 SMIP Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Researchers

Presenter

  • Ajay K. Gopal

Principal Investigators

  • Stefano R Tarantolo

  • Naresh Bellam

  • Tatyana Feldman

  • Anthony R Mato

  • Damian J Green

  • Melissa Griffin

  • Scott Stromatt

  • Andre Goy

Medical Centers

  • University of Washington, Seattle, WA

  • University of Alabama, Birmingham, AL

  • Department of Laboratory Medicine, University of Washington, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Retinal vein occlusion

  • Deep vein thrombosis

  • Follicular lymphoma

  • B-Cell Non-Hodgkin Lymphoma

  • Hypophosphatemic rickets

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Lymphomas

  • Insomnia

  • Anemia

Biomarkers

  • Nucleoside diphosphate kinase A

  • Src homology region 2 domain-containing phosphatase-1

  • White Blood Cell

Drug/Treatment

  • Diphenhydramine

  • Derma-Pax lotion

  • Hydrocortisone

  • Acetaminophen

  • Bendamustine

  • Alemtuzumab

  • Rituximab

  • Otlertuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved